Structures, targets and recent approaches in anti-leishmanial drug discovery and development.
- Published Version
Download (199Kb) | Preview
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis (CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug discovery and development.
|Faculty and Department:||Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection|
|Research Centre:||Antimicrobial Resistance Centre (AMR)
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Actions (login required)